Clinical trial
Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation
NCT00029328 · FDA Office of Orphan Products Development, U.S. Fed · Completed
Key facts
| NCT number | NCT00029328 |
|---|---|
| Title | Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation |
| Official title | Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Acute Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation |
| Lead sponsor | FDA Office of Orphan Products Development, U.S. Fed |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Respiratory Distress Syndrome, Adult, Bronchiolitis Obliterans, Pneumonia |
| Intervention type | Drug |
| Interventions | etanercept |
| Enrollment | 15 |
| Start date | Sep 1, 2001 |
| Completion | Sep 1, 2003 |
| First posted | Jan 11, 2002 |
| Last update posted | Mar 25, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: